Barclays raised the firm’s price target on Fortrea (FTRE) to $8 from $6 and keeps an Underweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea Holdings Appoints William J. Sharbaugh as Director
- Fortrea price target raised to $9.50 from $7 at Jefferies
- Fortrea price target raised to $14 from $9 at Baird
- Fortrea Expands Inducement Award Plan for New Hires
- Cautious Hold Rating for Fortrea Holdings Inc. Amid Revenue Growth and Modest Margins